Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2021

Latest Videos

View all
1:26
Ruxolitinib plus venetoclax for T-PLL: rationale and findings
Charles Herbaux • 25 May 2021
1:42
Exciting myeloma updates coming soon at EHA 2021
Enrique Ocio • 26 May 2021
2:52
Outcomes of haplo-TBF versus MUD-FB in AML
Ali Bazarbachi • 25 May 2021
2:15
The management of multiple myeloma in 2021
Claudio Cerchione • 25 May 2021

Multiple Myeloma

View all
1:41
ANCHOR: novel melflufen combinations in R/R myeloma
Enrique Ocio • 26 May 2021
2:53
MRD evaluation during ixazomib maintenance in myeloma
Bruno Paiva • 28 May 2021
2:51
18-month follow-up on CARTITUDE-1
Saad Usmani • 2 Jun 2021
2:38
Updates on belantamab mafodotin for myeloma
Claudio Cerchione • 25 May 2021

Lymphoma

View all
3:33
TG-1701: monotherapy & combination with U2 for CLL and lymphoma
Chan Yoon Cheah • 26 May 2021
1:46
Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
Charles Herbaux • 25 May 2021

CLL

View all
2:21
Outcomes of TP53-disrupted CLL patients treated with frontline ibrutinib
Andrea Visentin • 1 Jun 2021
4:11
IMPROVE: 33-month follow-up of MRD-driven therapy in CLL
Lydia Scarfò • 28 May 2021

ALL

View all
3:19
Blinatumomab plus ponatinib for Ph+ ALL
Nicholas Short • 25 May 2021
5:23
Redefining low risk high hyperdiploidy in pediatric ALL
Anthony Moorman • 8 Jun 2021

AML

View all
3:04
FF-10101-01: a novel FLT3 inhibitor for R/R AML
Mark Levis • 27 May 2021
3:00
KOMET-001: targeting menin-KMT2A in AML
Eunice Wang • 27 May 2021

MDS

View all
1:06
COMMANDS trial: luspatercept vs epoetin alfa in lower-risk MDS
Uwe Platzbecker • 1 Jun 2021
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021

MPNs

View all
1:49
Results from MANIFEST Phase II study of pelabresib for anemia associated with myelofibrosis
Srdan Verstovsek • 9 Jun 2021
1:27
JAKARTA and JAKARTA2: OS and PFS analysis of fedratinib in myelofibrosis
John Mascarenhas • 10 Jun 2021

Transplantation

View all
6:57
Downregulation of HLA expression in acute leukemia relapsed after transplantation
Hui Wang • 17 Jun 2021
4:33
INTEGRATE: 2-year follow-up of ibrutinib plus corticosteroids for cGvHD
David Miklos • 14 Jun 2021
2:26
Outcomes with RIC before second HSCT in secondary AML
Arnon Nagler • 14 Jun 2021
1:19
Narsoplimab increases platelets and decreases LDH in TA-TMA
Eleni Gavriilaki • 26 May 2021

Immuno-Oncology

View all
4:47
Sabatolimab plus HMAs in high-/very high-risk MDS and ND-AML
Andrew Brunner • 3 Jun 2021
1:40
ELEVATE-TN: 4-year follow-up shows PFS benefit of A or A+O over O+Clb for CLL
John Byrd • 3 Jun 2021

CAR-T & Cellular Therapies

View all
6:24
ZUMA-3 study update: brexucabtagene autoleucel for R/R ALL
Bijal Shah • 2 Jun 2021
3:22
CD20 targeted CAR-T: MB-106 in B-NHL and CLL
Mazyar Shadman • 25 May 2021

Latest Podcasts

Key updates on CAR-T & cellular therapy for AML
Latest updates in Hodgkin lymphoma from ISHL HL 2021
Post-EBMT highlights in acute myeloid leukemia
Updates for the management of MDS from ASH 2020
The content of VJHemOnc is intended for healthcare professionals